EBV-specific-CAR.CD30

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameEBV-specific-CAR.CD30
Drug Alias NameEBV-specific-CAR.CD30CAR.CD30 EBV-specific-CTLs
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionTumor necrosis factor receptor superfamily member 8 modulatorsT lymphocyte replacements
TargetsTumor necrosis factor receptor superfamily member 8
Therapy Area/IndicationsLymphoma, Non-HodgkinHodgkin Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesBaylor College Of MedicineTexas Children'S HospitalMethodist Hospital System
China Registration ClassN/A

Develop Information

Active CompaniesMethodist Hospital SystemTexas Children'S HospitalBaylor College Of Medicine
Inactive CompaniesN/A
Active IndicationsLymphoma, Non-HodgkinHodgkin Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A